Dr. Agarwal's Health Care lifts PAT 52% on 22% revenue growth
Strong FY26 numbers across the board, but a routine earnings release with an immaterial IPO expense reallocation. Growth was likely guided.
— 4 earlier stories on Dr. Agarwal's Health Care Ltd. →What's new
- Revenue up 21.6% YoY; EBITDA up 22.2%.
- PAT surges 52.4% YoY – the standout metric.
- Board reallocates ₹14.88 cr of unspent IPO expenses – 0.1% of market cap.
Why this matters
The earnings are strong, but the filing is standard and the numbers were within prior guidance. The real question is whether this growth rate can sustain into FY27 without fiscal tailwinds.
What we're watching
- FY27 guidance – can revenue growth stay above 20%?
- Any expansion plans or new hospital additions.
- Competitive pressure from other eye care chains.
The full read
Dr. Agarwal's Health Care closed FY26 with solid momentum: revenue climbed 21.6%, EBITDA 22.2%, and PAT jumped 52.4% – all year-on-year. The earnings release itself is routine, and the sole non-operating item – a ₹14.88 crore reallocation of unspent IPO proceeds – is negligible at 0.1% of market cap. The market likely had these numbers in mind after prior guidance and industry trends. So the filing confirms good performance but adds little new. The focus shifts to whether Dr. Agarwal can repeat this pace, especially as the base effects roll off.
Dr. Agarwal's Health Care Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on AGARWALEYE →- 21 May 2026 · 6:13 PM IST Dr. Agarwal's Health Care lifts PAT 52% on 22% revenue growth
- 46d ago Dr. Agarwal's Health Care Q4 transcript adds no new data
- 51d ago Dr. Agarwal's Health Care reports FY26 revenue of over ₹2,000 cr
- 51d ago Dr. Agarwal's profit jumps 52% on 21% revenue growth
- 51d ago Dr. Agarwal's Q4 profit jumps 52%, but the numbers were already priced in.